Australija - engleski - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - fluoxetine hydrochloride -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - fluoxetine hydrochloride -

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

carilion materials management - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® (valsartan) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluatio

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

carilion materials management - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - diovan® (valsartan) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluatio

Australija - engleski - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluoxetine hydrochloride -

Singapur - engleski - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - hydrochlorothiazide; valsartan - tablet, film coated - 25 mg - hydrochlorothiazide 25 mg; valsartan 160 mg

Singapur - engleski - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - valsartan - tablet, film coated - 160 mg - valsartan 160 mg

Singapur - engleski - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - valsartan - tablet, film coated - 80 mg - valsartan 80 mg

Singapur - engleski - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - hydrochlorothiazide; valsartan - tablet, film coated - 12.5 mg - hydrochlorothiazide 12.5 mg; valsartan 160 mg

Singapur - engleski - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - hydrochlorothiazide; valsartan - tablet, film coated - 12.5mg - hydrochlorothiazide 12.5mg; valsartan 80 mg